CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Visterra›
Analysis
Visterra

Visterra

Visterra develops antibody-based biologic therapies for kidney and other hard-to-treat diseases as an Otsuka subsidiary.

Operating headquarters
Waltham, MA, US🇺🇸
Founded
2008
Loading
Overview
M & A
Analysis
Compare
Fundraising
Employees
News
Library

Contents

  1. 01Competitive Strengths
  2. 02Competitive Risks
  3. 03Market Outlook
  1. 01Competitive Strengths
  2. 02Competitive Risks
  3. 03Market Outlook

Competitive Advantages

Visterra's HIEROTOPE platform combines disease-specific target analysis, epitope selection, and computational and experimental antibody design. Its approach includes single-cell multiomics, structure-based analysis, machine learning, and engineering for potency, specificity, half-life, and manufacturability.

The company has advanced sibeprenlimab from this research into clinical development and maintains additional investigational programs. Otsuka ownership gives Visterra access to a larger pharmaceutical group's clinical and commercial resources while its own Waltham team continues discovery work.

Source: visterrainc.com

Competitive Disadvantages

Visterra's antibody candidates face the clinical and regulatory uncertainty inherent in investigational biologics. The company's pipeline page says VOYXACT's continued accelerated approval may depend on confirmatory evidence of long-term clinical benefit from the ongoing Phase 3 VISIONARY study.

Commercialization of VOYXACT is conducted by Otsuka America Pharmaceutical, and the page attributes clinical development to Otsuka and, for another program, Serum Institute of India. This structure leaves Visterra dependent on related organizations for activities beyond its own research and early development; it does not establish that the collaborations are failing.

Source: visterrainc.com

Market Outlook

Visterra's current clinical-trial page lists sibeprenlimab studies in IgA nephropathy and Sjögren disease, plus a Phase 1 VIS171 trial in autoimmune disease. The pipeline page notes accelerated U.S. approval of VOYXACT for reducing proteinuria in adults with primary IgA nephropathy at risk of progression.

The near-term outlook turns on whether confirmatory testing establishes longer-term kidney benefit and whether other clinical programs show acceptable safety and efficacy. Visterra's antibody-engineering platform supports further candidates, but the official pages do not quantify commercial demand, expected sales, or approval probabilities.

Source: visterrainc.com